中国临床药学杂志2024，Vol.33Issue(10)：769-773,5.DOI:10.19577/j.1007-4406.2024.10.010
磺达肝癸钠在骨科大手术围术期抗纤溶药序贯抗凝治疗中的临床研究
Clinical study of fondaparinux in perioperative antifibrinolytic sequential anticoagulation therapy in major orthopedic surgery
摘要
Abstract
AIM To investigate the efficacy and safety of fondaparinux in perioperative anticoagulation therapy in patients undergoing major orthopedic surgery.METHODS From January 2020 to December 2021,89 patients who underwent major orthopedic surgery were randomly divided into control group(n=44)and experiment group(n=45).Patients in both groups received antifibrinolytic medication(tranexamic acid)followed by sequential anticoagulant therapy(the control group was given enoxaparin,while the experiment group was given fondaparinux).The incidence of venous thromboembolism(VTE),mortality,total blood loss,changes in hemoglobin(Hb),platelet count(PLT),coagulation function,and incidence of major bleeding events were observed.RESULTS The total blood loss between the control group and experiment group was(269.34±240.79)mL and(231.84±119.77)mL,respectively.There were no statistically significant differences in Hb and PLT in the control group and experiment group on preoperative and postoperative days 1,2,3,7,and 14(P＞0.05).The prothrombin time(PT)of experiment group was significantly longer than that of control group at 3 days after operation(P＜0.05).At 7 days after surgery,the activated partial thromboplastin time(APTT)of experiment group was significantly longer than that of control group(P＜0.05).Neither group experienced deep vein thrombosis or pulmonary thromboembolism.CONCLUSION It is safe and effective to apply fondaparinux to sequential anticoagulant therapy of antifibrinolytic agents during perioperative period of major orthopedic surgery,which is worthy of recommendation.关键词
深静脉血栓/抗凝/序贯疗法/依诺肝素钠/磺达肝癸钠Key words
deep vein thrombosis/anticoagulant/sequential therapy/enoxaparin/fondaparinux引用本文复制引用
黄歆,徐磊,谢威,杨浩森,熊德建,胡彦婷,汪瑜..磺达肝癸钠在骨科大手术围术期抗纤溶药序贯抗凝治疗中的临床研究[J].中国临床药学杂志,2024,33(10):769-773,5.基金项目
四川省医学会静脉血栓栓塞症防治(恒瑞)专项科研课题(编号2019HR23) （恒瑞）
